ClinicalTrials.gg
CompletedNCT01846299Updated May 23, 2016Results posted

To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

A Phase 3 interventional study of Sham control and Ranibizumab in Macular Edema (ME), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-05-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
23rd of 91
181 · median 50
Started
2013
with 9 others
Phase 3
25 of 91
none open now
Registered
50th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 23rd largest by enrollment, is one of 10 that started in 2013, is one of 25 in phase 3, and was the 50th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).

03

Conditions studied

  • Macular Edema (ME)

Keywords

  • Vision Impairment
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of active ME secondary to any causes (for adult patients: except diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO));
  • BCVA must be between ≥ 24 and ≤ 83 letters;
  • Visual loss should be mainly due to the presence of any eligible types of ME.

Exclusion criteria

Exclusion Criteria:

  • Women of ,
  • Active ;
  • History of stroke less than 6 months prior to screening;
  • Uncontrolled systemic inflammation or infection, related directly to the underlying causal disease of ME;
  • Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;
  • Any type of advanced, severe or unstable ocular disease or its reatment;
  • ME with a high likelihood of spontaneous resolution.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.

    Drug: Ranibizumab

  • Sham comparator
    Sham control

    Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.

    Other: Sham control

Interventions

  • OtherSham control

    The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

  • Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

    Time frame: Baseline, Month 2

Secondary outcomes

  1. Change From Baseline in BCVA in Study Eye up to Month 2

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

    Time frame: Baseline, Month 1, Month 2

  2. Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye

    CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  3. Change From Baseline in Central Subfield Volume (CSFV) in Study Eye

    CSFV was assessed OCT. A negative change from baseline indicates improvement.

    Time frame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  4. Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline

    The presence of intra-retinal fluid was assessed by OCT.

    Time frame: Month 2, Month 6, Month 12

  5. Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline

    The presence of subretinal fluid was assessed by OCT.

    Time frame: Month 2, Month 6, Month 12

  6. Number of Participants With Presence of Active Macular Edema (ME) Leakage

    The presence of active ME leakage was assessed by fluorescein angiography (FA).

    Time frame: Month 2

  7. Number of Participants Requiring Rescue Treatment at Month 1

    Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.

    Time frame: Month 1

  8. Average Change From Baseline in BCVA

    BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

    Time frame: Baseline (BL), month 1 through month 6, month 1 through month 12

  9. Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters

    VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Month 2, Month 6 , Month 12

  10. Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss

    VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Month 2, Month 6, Month 12

  11. Number of Participants With Ranibizumab Treatments

    The number of participants administered study treatments, according to treatment frequency, was assessed.

    Time frame: Month 12

  12. Number of Participants With Re-treatments

    The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.

    Time frame: Month 6, month 12

  13. Number of Primary Reasons for Decision to Treat by Investigator

    The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.

    Time frame: 12 months

07

Results

Posted May 23, 2016

Participant flow

A total of 181 participants were enrolled. Of these, 178 adults were randomized in a 2:1 ratio and considered for analysis. The 3 adolescent participants, non-randomized, received open-label treatment and were not included in the analyses. Therefore, the number enrolled = 181 differs from the number randomized = 178 in the participant flow.

Participant flow — Overall Study
MilestoneRanibizumabSham
Started11860
Full analysis set11760
Safety set11958
Completed10650
Not completed1210
Withdrew: Physician decision42
Withdrew: Protocol deviation10
Withdrew: Death12
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject16
Withdrew: Adverse event20

Outcome measures

PrimaryChange From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

Time frame:
Baseline, Month 2
Reported as:
Least squares mean · letters
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye
lettersRanibizumabSham With Ranibizumab
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye5.7 ± 0.812.9 ± 0.89
Statistical analysis
  • Ranibizumab vs Sham With Ranibizumab · Mixed Models Analysis · p = 0.0111 · Mean difference (net): 2.78 · 95% CI 0.40 to 5.16
SecondaryChange From Baseline in BCVA in Study Eye up to Month 2

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

Time frame:
Baseline, Month 1, Month 2
Reported as:
Least squares mean · letters
Change From Baseline in BCVA in Study Eye up to Month 2
lettersRanibizumabSham With Ranibizumab
Month 1 (n=116,59)4.7 ± 0.701.4 ± 0.98
Month 2 (n=114,59)5.8 ± 0.762.8 ± 1.05
SecondaryChange From Baseline in Central Subfield Thickness (CSFT) in Study Eye

CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · micrometers (um)
Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye
micrometers (um)RanibizumabSham With Ranibizumab
Month 1 (n=112,59)-83.6 ± 127.45-14.3 ± 97.36
Month 2 (n=112,59)-82.5 ± 140.06-30.6 ± 102.77
Month 3 (n=113,59)-86.5 ± 136.43-92.2 ± 129.85
Month 4 (n=109,57)-94.5 ± 141.55-95.5 ± 140.68
Month 5 (n=105,57)-98.6 ± 136.28-107.6 ± 142.22
Month 6 (n=109,54)-110.6 ± 133.10-84.1 ± 137.86
Month 7 (n=105,52)-113.3 ± 130.84-112.9 ± 148.13
Month 8 (n=105,51)-113.1 ± 127.11-107.7 ± 157.40
Month 9 (n=105,52)-111.6 ± 127.99-116.3 ± 146.43
Month 10 (n=103,50)-114.1 ± 131.12-116.6 ± 147.26
Month 11 (n=101,49)-112.1 ± 124.00-123.5 ± 140.65
Month 12 (n=103,50)-121.0 ± 124.67-116.8 ± 137.99
SecondaryChange From Baseline in Central Subfield Volume (CSFV) in Study Eye

CSFV was assessed OCT. A negative change from baseline indicates improvement.

Time frame:
Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · microliters (ul)
Change From Baseline in Central Subfield Volume (CSFV) in Study Eye
microliters (ul)RanibizumabSham With Ranibizumab
Month 1 (n=112,59)-0.296 ± 0.4570-0.032 ± 0.3969
Month 2 (n=112,59)-0.276 ± 0.5362-0.104 ± 0.3958
Month 3 (n=113,59)-0.322 ± 0.5812-0.348 ± 0.5075
Month 4 (n=109,57)-0.333 ± 0.5568-0.378 ± 0.5436
Month 5 (n=105,57)-0.383 ± 0.5592-0.401 ± 0.5893
Month 6 (n=109,54)-0.388 ± 0.5167-0.344 ± 0.5530
Month 7 (n=105,52)-0.438 ± 0.5267-0.438 ± 0.6098
Month 8 (n=105,51)-0.405 ± 0.5074-0.421 ± 0.6484
Month 9 (n=105,52)-0.446 ± 0.6066-0.444 ± 0.6210
Month 10 (n=103,50)-0.439 ± 0.6241-0.433 ± 0.6407
Month 11 (n=101,49)-0.406 ± 0.4871-0.459 ± 0.6157
Month 12 (n=103,50)-0.447 ± 0.4837-0.455 ± 0.5910
SecondaryNumber of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline

The presence of intra-retinal fluid was assessed by OCT.

Time frame:
Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline
ParticipantsRanibizumabSham With Ranibizumab
Month 2, Absent (n=112,59)9846
Month 2, Definite (n=112,59)1413
Month 6, Absent (n=109,55)9743
Month 6, Definite (n=109,55)1212
Month 12, Absent (n=103,50)7839
Month 12, Definite (n=103,50)2511
SecondaryNumber of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline

The presence of subretinal fluid was assessed by OCT.

Time frame:
Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline
ParticipantsRanibizumabSham With Ranibizumab
Month 2, Absent (n=113,59)7733
Month 2, Definite (n=110,55)3626
Month 6, Absent (n=109,55)7535
Month 6, Definite (n=109,55)3520
Month 12, Absent (n=104,50)7737
Month 12, Definite (n=103,50)2713
SecondaryNumber of Participants With Presence of Active Macular Edema (ME) Leakage

The presence of active ME leakage was assessed by fluorescein angiography (FA).

Time frame:
Month 2
Reported as:
Number · Participants
Number of Participants With Presence of Active Macular Edema (ME) Leakage
ParticipantsRanibizumabSham With Ranibizumab
Number of Participants With Presence of Active Macular Edema (ME) Leakage9653
SecondaryNumber of Participants Requiring Rescue Treatment at Month 1

Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \> 5 letters due to disease activity from baseline to Month 1.

Time frame:
Month 1
Reported as:
Number · Participants
Number of Participants Requiring Rescue Treatment at Month 1
ParticipantsRanibizumabSham With Ranibizumab
Number of Participants Requiring Rescue Treatment at Month 100
SecondaryAverage Change From Baseline in BCVA

BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.

Time frame:
Baseline (BL), month 1 through month 6, month 1 through month 12
Reported as:
Mean · letters
Average Change From Baseline in BCVA
lettersRanibizumabSham With Ranibizumab
Average change from BL, month 1 through month 66.39 ± 8.4054.50 ± 8.095
Average change from BL, month 1 through month 127.40 ± 9.0525.82 ± 8.927
SecondaryNumber of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Month 2, Month 6 , Month 12
Reported as:
Number · Participants
Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters
ParticipantsRanibizumabSham With Ranibizumab
Month 2, Gain of >= 15 letters (n=114,59)267
Month 2, Gain of >= 10 letters (n=114,59)3511
Month 2, Gain of >= 5 letters (n=114,59)5519
Month 2, Gain of >= 1 letter (n=114,59)8038
Month 6, Gain of >= 15 letters (n=111,55)3015
Month 6, Gain of >= 10 letters (n=111,55)4121
Month 6, Gain of >= 5 letters (n=111,55)6734
Month 6, Gain of >= 1 letters (n=111,55)8740
Month 12, Gain of >= 15 letters (n=106,50)4422
Month 12, Gain of >= 10 letters (n=106,50)5527
Month 12, Gain of >= 5 letters (n=106,50)7237
Month 12, Gain of >= 1 letters (n=106,50)8642
SecondaryNumber of Participants With > 1, > 5, > 10 and > 15 Letters Loss

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Month 2, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss
ParticipantsRanibizumabSham With Ranibizumab
Month 2, Loss of >1 letter (n=114,59)179
Month 2, Loss of >5 letters (n=114,59)84
Month 2, Loss of >10 letters (n=114,59)23
Month 2, Loss of >15 letters (n=114,59)00
Month 6, Loss of >1 letter (n=111,55)1412
Month 6, Loss of >5 letters (n=111,55)57
Month 6, Loss of >10 letters (n=111,55)34
Month 6, Loss of >15 letters (n=111,55)11
Month 12, Loss of >= 1 letter (n=106,50)105
Month 12, Loss of >= 5 letters (n=106,50)63
Month 12, Loss of >= 10 letters (n=106,50)23
Month 12, Loss of >= 15 letters (n=106,50)12
SecondaryNumber of Participants With Ranibizumab Treatments

The number of participants administered study treatments, according to treatment frequency, was assessed.

Time frame:
Month 12
Reported as:
Number · Participants
Number of Participants With Ranibizumab Treatments
ParticipantsRanibizumabSham With RanibizumabSham Without Ranibizumab
Frequency of injections = 0002
Frequency of injections = 11360
Frequency of injections = 2530
Frequency of injections = 31470
Frequency of injections = 4350
Frequency of injections = 51770
Frequency of injections = 67110
Frequency of injections = 7600
Frequency of injections = 81300
Frequency of injections = 9360
Frequency of injections = 1012110
Frequency of injections = 11600
Frequency of injections = 122000
SecondaryNumber of Participants With Re-treatments

The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.

Time frame:
Month 6, month 12
Reported as:
Number · Participants
Number of Participants With Re-treatments
ParticipantsRanibizumabSham With RanibizumabSham Without Ranibizumab
Month 6, Frequency of re-treatment = 134150
Month 6, Frequency of re-treatment = 21530
Month 12, Frequency of re-treatment = 121120
Month 12, Frequency of re-treatment = 22470
Month 12, Frequency of re-treatment = 31350
Month 12, Frequency of re-treatment = 4550
Month 12, Frequency of re-treatment = 5300
SecondaryNumber of Primary Reasons for Decision to Treat by Investigator

The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.

Time frame:
12 months
Reported as:
Number · Number of primary reasons
Number of Primary Reasons for Decision to Treat by Investigator
Number of primary reasonsRanibizumabSham With RanibizumabSham Without Ranibizumab
Vision impairment38220
OCT abnormality6373451
FA abnormality1150
Color fundus photography abnormality000
Clinical abnormality300
Without documentation (missing reason)000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5mg—15/119 (12.6%)58/119 (48.7%)
Sham With Ranibizumab 0.5mg—6/56 (10.7%)21/56 (37.5%)
Sham Without Ranibizumab 0.5mg—1/2 (50%)0/2 (0%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventRanibizumab 0.5mgSham With Ranibizumab 0.5mgSham Without Ranibizumab 0.5mg
Basilar artery thrombosisNervous system disorders0/1190/561/2
Brain stem strokeNervous system disorders0/1190/561/2
Cardio-respiratory arrestCardiac disorders0/1191/560/2
Corneal oedema (Fellow treated eye)Eye disorders0/1191/560/2
GastritisGastrointestinal disorders0/1191/560/2
Pancreatitis acuteGastrointestinal disorders0/1191/560/2
HypokalaemiaMetabolism and nutrition disorders0/1191/560/2
Mobility decreasedMusculoskeletal and connective tissue disorders0/1191/560/2
Muscular weaknessMusculoskeletal and connective tissue disorders0/1191/560/2
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/560/2
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRanibizumab 0.5mgSham With Ranibizumab 0.5mgSham Without Ranibizumab 0.5mg
Conjunctival haemorrhage (Study eye)Eye disorders11/1197/560/2
NasopharyngitisInfections and infestations12/1192/560/2
Visual acuity reduced (Study eye)Eye disorders11/1193/560/2
Eye pain (Study eye)Eye disorders10/1192/560/2
Macular oedema (Study eye)Eye disorders7/1192/560/2
Macular oedema (Fellow untreated eye)Eye disorders1/1193/560/2
InfluenzaInfections and infestations6/1193/560/2
Intraocular pressure increased (Study eye)Investigations6/1193/560/2
Cystoid macular oedema (Study eye)Eye disorders6/1190/560/2
Dry eye (Study eye)Eye disorders6/1191/560/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RanibizumabShamTotal
Mean63.5 ± 13.9761.8 ± 15.5562.9 ± 14.50
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabShamTotal
Female452368
Male7337110
08

Study locations

61 sites
  • Novartis Investigative Site
    Sydney, New South Wales 2000, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    South Launceston, Tasmania 7249, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2E1, Canada
  • Novartis Investigative Site
    Plzen, 301 00, Czech Republic
  • Novartis Investigative Site
    Praha 10, 100 34, Czech Republic
  • Novartis Investigative Site
    Bordeaux Cedex, F-33076, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Paris cedex 10, 75010, France
  • Novartis Investigative Site
    Saint-Jean, 31240, France
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Freiburg i. Br, 79106, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Kfar-Sava, 4428164, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Rehovot, 7610001, Israel
  • Novartis Investigative Site
    Tel-Aviv, 6423906, Israel
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milano, MI 20123, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Torino, TO 10122, Italy
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 137-701, Korea, Republic of
  • Novartis Investigative Site
    Busan, 602-739, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 150-034, Korea, Republic of
  • Novartis Investigative Site
    Riga, 1002, Latvia
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Tilburg, NL-5022GC, Netherlands
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 119021, Russian Federation
  • Novartis Investigative Site
    Moscow, 127486, Russian Federation
  • Novartis Investigative Site
    Singapore, 168751, Singapore
  • Novartis Investigative Site
    Banska Bystrica, 97517, Slovakia
  • Novartis Investigative Site
    Trencin, 91171, Slovakia
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Sant Cugat, Catalunya 08190, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Binningen, 4102, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Birmingham, B18 7QU, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Sunderland, SR2 9HP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2013
First posted
May 3, 2013
Start
Oct 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
May 23, 2016
Last update
May 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01846299
Responsible party
Sponsor
First posted
May 3, 2013
Start date
Oct 2013
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
May 23, 2016
Last update
May 23, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion